Innova and TGR Enter Co-Marketing Agreement for Complementary Core Biotechnologies
|
By LabMedica International staff writers Posted on 02 Feb 2014 |
Combining ELISA technology from TGR BioSciences (Adelaide, Australia) with conjugation kits from Innova Biosciences (Cambridge, UK) improves ELISA sensitivity and reduces cost.
TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.
“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”
Related Links:
TGR BioSciences
Innova Biosciences
TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.
“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”
Related Links:
TGR BioSciences
Innova Biosciences
Latest Industry News
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
- Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
Tracking gene-expression changes in the brain is crucial for understanding neurological diseases, yet current monitoring tools are invasive or unable to capture subtle activity shifts over time.... Read more
World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
Type 1 Diabetes (T1D) affects more than eight million people worldwide, with numbers expected to rise sharply. While most cases are genetically driven, only one in ten patients has a family history, making... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more






 Analyzer.jpg)

